3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Tumor-Agnostic
2
Other hematologic neoplasm
2
Lymphoid
2
Dermatologic
1
CNS
1
Conditions
Melanoma
3
Brain Neoplasms
2
Uveal Melanoma
1
Thyroid Cancer, Papillary
1
Sarcoma
1
Salivary Gland Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Noonan Syndrome 6
1
Neuroendocrine Tumors
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Lymphoproliferative Disorders
1
Lymphoma, Large-Cell, Anaplastic
1
Hematologic Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
pembrolizumab
40
Nivolumab
18
trametinib
13
Cyclophosphamide
13
dabrafenib
11
Vemurafenib
10
Interleukin-2
10
Ipilimumab
9
fludarabine
7
Docetaxel
7
fludarabine phosphate
6
cemiplimab
6
Paclitaxel
6
Cisplatin
6
Carboplatin
6
atezolizumab
5
Radiotherapy
5
Drug Therapy
5
Dacarbazine
5
Blood Specimen Collection
5
Biopsy
5
poly ICLC
4
binimetinib
4
Therapeutics
4
Psychiatric Rehabilitation
4
sotigalimab
3
montanide ISA 51
3
encorafenib
3
cobimetinib
3
budigalimab
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms
×
entrectinib
×
Dermatologic
×
Clear all
NCT05770544
2025-11-24
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled